CoChat

Metformin Improves Endothelial Vascular Reactivity in First-Degree Relatives of Type 2 Diabetic Patients With Metabolic Syndrome and Normal Glucose Tolerance

de Aguiar, Luiz Guilherme Kraemer, Bahia, Luciana R., Villela, Nivaldo, Laflor, Camila, Sicuro, Fernando, Wiernsperger, Nicolas, Bottino, Daniel, Bouskela, Eliete · 2006 · Diabetes Care
Cited by 120

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

OBJECTIVE—Endothelial dysfunction is an early marker of atherosclerosis seen in type 2 diabetic subjects. Metformin is commonly used in the treatment of type 2 diabetes and has known vasculoprotective effects beyond its hypoglycemic ones. We aimed to investigate the vascular effects of metformin in first-degree relatives with metabolic syndrome of type 2 diabetic patients. RESEARCH DESIGN AND METHODS—The study included 31 subjects (age 38.3 ± 7.6 years and BMI 36.3 ± 5.2 kg/m2), who were first-degree relatives of type 2 diabetic patients and who had metabolic syndrome and normal glucose tolerance. The subjects were randomly assigned 1:1 in a double-blind fashion to receive placebo (n = 15) or metformin (n = 16). Endothelial function was assessed by venous occlusion plethysmography, measuring forearm blood flow (FBF) and vascular resistance responses to three intra-arterial infusions of endothelium-dependent (acetylcholine 7.5, 15, and 30 μg/min) and independent (sodium nitroprusside 2, 4, and 8 μg/min) vasodilators. Weight, BMI, systolic and diastolic blood pressure, waist, and laboratory parameters (lipid profile and fasting plasma glucose [FPG]) were assessed at baseline and after treatment. RESULTS—The metformin and placebo groups did not differ in anthropometric, clinical, laboratory, and vascular measurements at baseline. The metformin group had decreased weight, BMI, systolic blood pressure, and FPG and improved lipid profile. Endothelium-dependent FBF responses were also improved, without any effect on endothelium-independent responses. There was no correlation between the improvement on FBF responses and the observed changes on anthropometric, clinical, and laboratory parameters. CONCLUSIONS—We concluded that metformin improved vascular endothelial reactivity in first-degree relatives with metabolic syndrome of type 2 diabetic patients, independently of its known antihyperglycemic effects.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc05-2146

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Research works printed but not linked: 22

  1. Goff DC Jr, Zaccaro DJ, Haffner SM, Saad MF: Insulin sensitivity and the risk of incident hypertension: insights from the Insulin Resistance Atherosclerosis Study. Diabetes Care 26: 805–809,2003 · DOI · Paper page
  2. Bonora E, Formentini G, Calcaterra F, Lombardi S, Marini F, Zenari F, Saggiani F, Poli M, Perbelini S, Rafaelli A, Cacciatori V, Santi L, Targher G, Bonadona R, Muggeo M: HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from Verona Diabetes Complications Study. Diabetes Care 25: 1135–1141,2002 · DOI · Paper page
  3. Palmer RM, Ferrige AG, Moncada S: Nitric oxide release accounts for the biological activity of endothelium-dependent relaxing factor. Nature 327: 524–526,1987 · DOI · Paper page
  4. Schächinger V, Britten MB, Zeiher AM: Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 101: 1899–1906,2000 · DOI · Paper page
  5. Hsueh WA, Quinones MJ: Role of endothelial dysfunction in insulin resistance. Am J Cardiol 92: 10J–17J,2003 · DOI · Paper page
  6. Jang Y, Kim OY, Ryu HJ, Kim JY, Song SH, Ordovas JM, Lee JH: Visceral fat accumulation determines postprandial lipemic response, lipid peroxidation, DNA damage, and endothelial dysfunction in nonobese Korean men. J Lipid Res 44: 1356–1364,2003 · DOI
  7. Balletshofer BM, Rittig K, Enderle M, Volk A, Maerker E, Jacob S, Matthei S, Rett K, Häring H: Endothelial dysfunction is detectable in young normotensive first-degree relatives of subjects with type 2 diabetes in association with insulin resistance. Circulation 101: 1780–1784,2000 · DOI · Paper page
  8. Caballero AE, Arora S, Saouaf R, Lim SC, Smakowski P, Park JY, King GL, LoGerfo FW, Horton ES, Veves A: Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetes. Diabetes 48: 1856–1862,1999 · DOI · Paper page
  9. Tooke J: Endotheliopathy precedes type 2 diabetes. Diabetes 21: 2047–2049,1998 · DOI
  10. UK Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352: 854–865,1998 · DOI · Paper page
  11. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285: 2486–2497,2001 · DOI · Paper page
  12. American Diabetes Association: Diagnosis and classification of diabetes mellitus (Position Statement). Diabetes Care 27: S5–S10,2004 · DOI · Paper page
  13. Hirooka Y, Imaizumu T, Tagawa T, Shiramoto M, Endo T, Ando SI, Takexhita A: Molecular and cellular responses: effects of l-arginine on impaired acetylcholine-induced and ischemic vasodilation of the forearm in the patients with heart failure. Circulation 90: 658–668,1994 · DOI · Paper page
  14. Jager J, Kooy A, Lehert PH, Bets D, Wulffelé MG, Teerlink T, Scheffer PG, Schalkwijk CG, Donker AJM, Stehouwer CDA: Effects of short-term treatment with metformin on markers of endothelial function and inflammatory actitivity in type 2 diabetes mellitus: a randomized, placebo-controlled trial. J Intern Med 257: 100–109,2005 · DOI · Paper page
  15. Fichtlscherer S, Breuer S, Zeiher AM: Prognostic value of systemic endothelial dysfunction in patients with acute coronary syndrome. Circulation 110: 1926–1932,2004 · DOI · Paper page
  16. Giannarelli R, Aragona M, Coppelli A, Del Prato S: Reducing insulin resistance with metformin: the evidence today. Diabet Med 29: 6S28–6S35, 2003 · DOI · Paper page
  17. Sirtori CR, Franceschini G, Gianfransceschi G: Metformin improves peripheral vascular flow in normohyperlipidemic patients with arterial disease. J Cardiovasc Pharmacol 6: 914–923,1984 · DOI
  18. Wiernsperger NF: Metformin: intrinsic vasculoprotective properties. Diabetes Technol Ther 2: 259–272,2000 · DOI
  19. Grant PJ: Beneficial effects of metformin on haemostasis and vascular function in man. Diabet Med 29: 6S44–6S52, 2003 · DOI · Paper page
  20. Katakam PVG, Ujhelyi MR, Hoenig M, Miller AW: Metformin improves vascular function in insulin-resistant rats. Hypertension 35: 108–112,2000 · DOI · Paper page
  21. Dagher Z, Ruderman N, Tornheim K, Ido Y: Acute regulation of fatty acid oxidation and AMP-activated protein kinase in human umbilical vein endotehlial cells. Circ Res 88: 1276–1282,2001 · DOI · Paper page
  22. Ming-Hui Z, Kirkpatrick SS, Davis BJ, Nelson JS, Wiles WG, Schlattner U, Neumann D, Brownlee M, Freeman MB: Activation of the AMP-activated protein kinase by the anti-diabetic drug metformin in vivo: role of mitochondrial reactive nitrogen species. J Biol Chem 279: 43940–43951,2004 · DOI · Paper page

Cited by

Metadata

Authors
de Aguiar, L. G. K., Bahia, L. R., Villela, N., Laflor, C., Sicuro, F., Wiernsperger, N., Bottino, D., & Bouskela, E.
Venue
Diabetes Care
Published
2006-05-01
Volume
29
Issue
5
Pages
1083-1089
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2147713686
Cited by
120
References
8
FWCI
7.67
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.